Insmed Incorporated
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- William H. Lewis
- Full Time Employees
- 1,664
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 700 US Highway 202/206 Bridgewater NJ United States of America 08807
- IPO Date
- Jun 1, 2000
- CIK
- 0001104506
- Website
- insmed.com
- Similar Companies
- Business
- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company founded in 1988 and headquartered in Bridgewater, New Jersey, focuses on rare diseases with investigational and approved therapies in pulmonary, inflammatory, and other serious conditions; its approved products include ARIKAYCE (amikacin liposome inhalation suspension) for Mycobacterium avium complex lung disease in adults with limited treatment options and BRINSUPRI (brensocatib), a first-in-class neutrophil elastase inhibitor for non-cystic fibrosis bronchiectasis; the company advances a pipeline encompassing TPIP for pulmonary arterial hypertension, INS1201, and preclinical programs in gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, serving patients primarily through clinical trials and commercial launches targeting chronic lung diseases. Insmed operates 9 corporate offices and 4 global research sites across the United States, Europe, Japan, and other regions, with over 1,500 employees as of mid-2025. Recent developments include FDA approval of BRINSUPRI in 2025 and its subsequent European Union approval, topline results from the Phase 2b pulmonary arterial hypertension study and Phase 3 ASPEN study in 2024-2025, the opening of a new research lab in Cambridge, UK, a proposed $650 million public offering of common stock in June 2025, raised full-year 2025 ARIKAYCE revenue guidance to $420-430 million, and repeated recognition as the No. 1 biopharma employer by Science magazine.
Company News
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
Insmed: Expensive Stock, But Discount To Recent Highs Makes Bull Case
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
Insmed Expands Community Impact During Fifth Annual Global Day of Good
Insmed Incorporated (INSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Insmed Incorporated (INSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Insmed: A Strong Launch And A Much Bigger Peak Sales Opportunity
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Insmed to Present at September 2026 Investor Conferences
Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal
Alger Mid Cap 40 ETF Q2 2026 Portfolio Review
BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
Invesco Discovery Mid Cap Growth Fund Q2 2026 Portfolio Performance
Biotech Is Booming, But These 2 Stocks Missed the Memo
Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake
Insmed Q2 Earnings Call Highlights
Insmed Incorporated (INSM) Q2 2026 Earnings Call Transcript
Insmed (INSM) Reports Q2 Earnings: What Key Metrics Have to Say